The development of a PET radioligand for imaging 5-hydroxytryptamine (5-HT) 6 receptors in the brain would, for the first time, enable in vivo imaging of this target along with assessment of its involvement in disease pathophysiology. In addition, such a tool would assist in the development of novel drugs targeting the 5-HT6 receptor.
|Number of pages||9|
|Journal||Journal of nuclear medicine : official publication, Society of Nuclear Medicine|
|Early online date||5 Jan 2012|
|Publication status||Published - 1 Feb 2012|